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Insulin-like growth factor-I gene expression in the tibial epiphyseal
growth plate of growth hormone-treated uremic rats. To identify the
molecular mechanisms involved in long bone growth of uremic animals,
we evaluated the effects of recombinant human growth hormone (rhGH)
supplementation on whole body growth, growth plate morphometrics, and
insulin-like growth factor-I (IGF-I) gene expression in the tibial epiphy-
seal growth plates of uremic rats. Uremia was induced by a two-stage
subtotal nephrectomy (Nx) of 30-day-old rats, followed by rhGH (N = 6)
or saline (N = 6) treatment from day 56 to day 70 of age. Controls (N =
4) were sham decapsulated. Treatment with rhGH on Nx animals caused:
(1) a significant increase in weight, (2) longitudinal growth similar to
controls, and (3) increased total growth plate width predominantly due to
an increase in hypertrophic zone width. rhGH increased IGF-I mRNA
abundance in both zones, but the increase was greater in the proliferative
zone. These changes were accompanied by concomitant alterations in
IGF-I immunoreactivity. In uremic animals, therefore, rhGH treatment
induces local IGF-I gene expression in the growth plate and increases the
hypertrophic zone width but not the proliferative zone width. The latter
suggests resistance to IGF-I action in that zone.
The growth hormone/insulin-like growth factor (GH/IGF) axis
is the major hormonal system regulating bone growth [1, 2].
Growth hormone has been shown to interact directly with chon-
drocytes in the tibial epiphyseal growth plate of the rat, and to
promote an increase in total plate width [3—5]. The regulatory
influence of GH on IGF-I mRNA expression and IGF-I immu-
noreactivity in the tibia! epiphyseal growth plate of the rat has
been demonstrated in the rhGH-treated hypophysectomized an-
imal [6, 7]. Furthermore, the role of IGF-I as the major effector of
GH actions at the level of the growth plate was demonstrated by
the capacity of the antibody against IGF-I to nullify the stimula-
tory effect of unilateral hind limb infusion of GH on tibial
epiphyseal growth plate width [8]. In patients with chronic renal
failure (CRF) who are growth-retarded, serum GH concentra-
tions are elevated [9, 10], and IGF-I concentrations are normal or
increased [11—13], reflecting the presence of resistance to the
growth promoting actions of GH/IGF-L Recent evidence showing
that exogenous supplementation with rhGH can improve linear
growth in CRF children with stunted growth [14—17] suggests that
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the relative resistance to growth promoting actions of endogenous
GH can be overcome by higher concentrations of GH. The
mechanism by which GH supplementation improves longitudinal
bone growth in CRF is unknown.
We hypothesized that the retardation of linear bone growth in
CRF is due to a decreased production of IGF-I by growth plate
chondrocytes with or without decreased sensitivity of these cells to
respond to IGF-I synthesized locally in response to GH. As a
consequence, higher dosages of GH are required to treat this
growth retardation, To examine the molecular mechanisms by
which longitudinal bone growth is regulated in uremia, we exam-
ined the distribution of IGF-I mRNA and peptide in the growth
plate chondrocytes of nephrectomized uremic rats treated with
rhGH or saline. This was combined with measurements of growth
plate morphometrics and physical measurements of the rats.
Methods
Animals and tissue preparation
Sixteen male Sprague-Dawley rats (Charles River Laboratories,
Boston, MA, USA) at the age of 30 days underwent a standard
two-stage 5/6th nephrectomy (Nx, N = 12) to create experimental
uremia, or sham decapsulation (S, N = 4) preserving the adrenal
gland as previously published [18]. After the second stage surgery,
rats were allowed an 18 day period of observation to develop a
stable state of chronic renal insufficiency. During this time and
throughout the study, rats were maintained on a standard 22.5%
protein rat chow (Prolab R-M-H 3200 meal, Agway Inc., Syracuse,
NY, USA) with free access to tap water. At 56 days of age, six Nx
rats (Nx + GH) began receiving daily, at 10:00 hours, intraperi-
toneal (i.p.) injections of 3 IU (1 mg) recombinant human growth
hormone (rhGH; Biosynthetic Human Growth Hormone, Lot
#979 HG9, Eli Lilly & Co., Indianapolis, IN, USA). The remain-
ing six Nx rats (Nx) and the four S rats received an equal volume
of i.p. saline daily at the same time. At 70 days of age, the rats
were anesthetized with methoxyflurane, blood for serum analysis
was obtained from the right atrium, and the rats were sacrificed
via transcardial fixation using 4% paraformaldehyde and 0.2%
glutaraldehyde (Electron Microscopy Sciences, Ft. Washington,
PA, USA) in 70 m phosphate buffer, pH 7.0. Tibias were excised,
broken at the midshaft, and a further 5 ml of fixative was infused
intraosseously just below the tibial epiphyseal growth plate.
Thereafter, the tibias were split in the midline sagittal plane and
further immersed in the same fixative for 18 hours at 4°C. The
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tibias were then washed in 10 m phosphate buffered saline (PBS)
over the next 48 hours. For decalcification, they were then
immersed in 10% ethylenediamine tetraacetic acid (EDTA) in
PBS, pH 7.0, at 4°C for 72 hours with a change of solution three
times every 24 hour period, and then embedded in paraffin. Tissue
sections for immunohistochemistry were prepared at 10 m
thickness by standard techniques and mounted on poly-L-lysine
coated slides, baked at 45°C for 48 hours, and stored at room
temperature until processing. Tissue sections for in situ hybridiza-
tion histochemistry (5 tim) were mounted onto Superfrost Plus
slides (Fisher Scientific Co., Springfield, NJ, USA) and baked at
55°C for two to four days, and stored at room temperature until
processing.
For morphometric analysis, six sections (4 tim) were cut from
each tibial half and mounted onto glass slides, then stained with
hematoxylin and eosin (H&E). These slides were subsequently
photomicrographed using a lOx objective lens and a 2.5x pro-
jection lens (the enlargement factor from negative to print = 4x).
Print measurements (in cms) were converted to rm accordingly.
When a column of chondrocytes was interrupted, the zone
measurements were continued in an adjacent column in a chon-
drocyte which maintained the same morphometric appearance as
the cell in the column that was interrupted. Although precise
morphometric criteria of distinguishing between proliferative and
hypertrophic cells at the boundary between these two zones in the
stained section do not exist, the criteria for identification of
chondrocyte morphology as described by Vaughn [19] and Brigh-
ton [201 were utilized. Thus proliferative chondrocytes were
identified by their flattened appearance, longitudinal columns and
narrow transverse septa, and hypertrophic chondrocytes by their
change to a spherical, enlarged, hydrated appearance reflected in
both transverse and longitudinal dimensions with the develop-
ment of lacunae. As noted by Brighton [20], this morphologic
change is abrupt and can be identified with an accuracy of one to
two cells. Total plate width was measured as the distance from
bone matrix in the reserve zone to bone matrix at the juncture
between the zone of calcifying cartilage and developing trabeculae
of the metaphysis. This bone matrix is easily identifiable by its
bright pink color on H&E staining as specified by Cormack [211.
Seven to ten measurements per growth plate yielded a total of 45
to 60 measurements from six sections of each bone. Mean and
standard deviation values for total plate width, hypertrophic zone
width, and proliferative zone width were calculated and compared
as described below.
Serum biochemistiy
Serum urea nitrogen was measured using an autoanalyzer
(Astra, Beckman Instruments, Brea, CA, USA), and serum cre-
atinine was determined using a Beckman Analyzer (Beckman
Instruments).
Serum IGF-I concentrations were determined as previously
described [22]. IGFs were separated from IGFBPs by acid treat-
ment followed by gel filtration chromatography on a 0.9 X 28 cm
column of Sephadex G-50 fine (360 X 12 mm, flow rate 25 mI/hr),
and eluted with acetic acid at room temperature. The primary
antiserum used was rabbit anti-human IGF-I (provided by Drs.
J.J. Van Wyk and L.E. Underwood, Department of Pediatrics,
University of North Carolina, Chapel Hill, through the National
Pituitary Agency, NIH) in a final assay dilution of 1:12,000.
In Situ hybridization
In situ hybridization histochemistry was performed as previ-
ously published [23, 24], with some modifications. After rehydra-
tion of paraffinized sections through xylene to descending concen-
trations of alcohols and into PBS, tissue sections were incubated
sequentially in the following solutions: 0.2% Triton X-100 in PBS
in one hour at room temperature, proteinase-K (1 gIml) in 100
mM Tris and 50 mivi EDTA (pH 8.0) for 30 minutes at 37°C, and
acetic anhydride (0.25%) in triethanolamine buffer (Sigma) for 10
minutes at room temperature. The sections were then dehydrated
through a graded ethanol series, air dried, and prehybridized with
lx hybridization buffer (0.3 M NaCl, 20 mrvi Tris-HC1, pH 8.0, 1
mM EDTA, lx Denhardt's solution, 500 .tg/ml yeast transfer
RNA, 100 .tg/ml denatured salmon sperm DNA, 10% dextran
sulphate, 0.1% SDS, 100 mrs dithiothreitol, and 50% formamide)
for two hours at 42°C. Tissue sections were hybridized with
35S-labeled IGF-I antisense RNA probes generated from a 0.5 kb
rat IGF-I cDNA encoding the mature IGF-l (a gift from Dr. Liam
Murphy, University of Manitoba, Winnipeg, Manitoba, Canada
[25]) subcloned into a pGEM-4 vector (Promega Co., Madison,
WI, USA), radiolabeled to a specific activity of io cpm/pg, and
used at the concentration of I O cpm/ml in lx hybridization buffer
overnight at 45°C. Tissue sections were then incubated in 1 X
hybridization buffer for 10 minutes at 45°C, treated with RNAse A
(20 ig/m1) in a buffer (0.5 M NaCl, 10 msi Tris pH 8.0, 1 mM
EDTA) for 30 minutes at 37°C and washed with SSC (1 x SSC =
0.15 M NaCI, 0.015 M sodium citrate) as follows: 2X SSC, twice for
30 minutes at room temperature; 2X SSC, four times for 30
minutes at 45°C; 0.lx SSC, twice for 15 minutes at room
temperature. Tissue sections were dehydrated through a graded
ethanol series to 100% ethanol, air dried, and exposed to X-ray
film for 10 hours at —70°C. Slides were then coated with photo-
emulsion (NTB-3 nuclear track emulsion, Eastman Kodak, Roch-
ester, NY, USA), and exposed at 4°C for four to six weeks. The
photoemulsion was developed in D-19 developer (Eastman
Kodak), fixed, and the sections were stained with Harris' hema-
toxylin and eosin, and mounted using Permount.
The specificity of in situ hybridization was demonstrated by the
lack of specific autoradiographic signal when adjacent tissue
sections were hybridized (as above) with 35S-radiolabeled IGF-I
sense RNA probe (Fig. 1 A and B).
Immunohistochemisty
Immunohistochemistiy for IGF-I was performed using the
avidin-biotin-peroxidase technique [26, 27] as previously de-
scribed [28]. Briefly, tissue sections were deparaffinized in xylene,
and rehydrated in descending concentrations of ethanol (100%,
95%, 70%) into PBS. Endogenous peroxidase activity was blocked
by incubating the tissue sections in 1% hydrogen peroxide in PBS
for 10 minutes. After the PBS rinse, tissue sections were incubated
with 0.125% trypsin in distilled water for 10 minutes, and then
incubated with antiserum against human (h) IGF-I (#878/4, a gift
from Drs. Peter Gluckman and Bernhard Brier, University of
Auckland, New Zealand [29]) (1:3,000) at 4°C for 48 hours. This
antiserum was raised in rabbits against recombinant human IGF-I
and has a cross-reactivity of less than 0.05% with IGF-1I, and none
with insulin in radioimmunoassays [29]. This antiserum has been
used to identify IGF-I specifically in tissues of various species
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Fig. 1. Brightfield photomicrographs of tibial epiphyseal growth plates from S rats hybridized in situ with 35S-radiolabeled rat IGF-I antisense RNA probe
(A) and sense RNA probe (B), and immunostained with a specific antiserum against IGF-I (C) and with an antiserum immunoabsorbed with 0.1 p.M IGF-I
prior to immunohistochemist,y (D). Scale bar = 100 pm. P = proliferative zone, H = hypertrophic zone. Figures B and D show specificity of the in situ
hybridization and immunohistochemistry, respectively.
Table 1. Anthropomorphic data
Data S Nx Nx±GH
Start of study
Weight g 87 2 89 7 86 7
Length cm 24 0.5 24 0.5 24 1
End of study
Weight g 357 27 280 346 22
Length cm 41 1.4 39 0.8" 40 1.6
Beginning of R
Weight g 278 24 215 18" 238 33
Length cm 36 1 34 1 36 2
Gain with R
Weight g 79 4 65 14" 97 15
Length cm 5 1 4 1.0 5 1.0
Data are mean SD. R, is treatment with rhGH or saline. Data are at
30 days of age prior to surgery (Start of study), at 56 days of age prior to
treatment (Beginning of R), and at 70 days of age after completion of
treatment (End of study and gain with R).
ap< 0.05 Nxvs. S
"P < 0.05 Nx vs. Nx + GH
including rat [24], sheep [231, and human [301. Positive immuno-
reactivity was identified by the avidin-biotin-peroxidase technique
using the Elite Vectastain kit (Vector Laboratories, Burlingame,
CA, USA) with diaminobenzidine (DAB, 3', 3'-diaminobenzidine
tetrachioride dihydrate, Sigma Chemical Co., St. Louis, MO,
USA) as a chromagen. Tissue sections were washed, dehydrated,
and mounted with Permount© (Fisher Scientific). Specificity of
the antiserum was demonstrated by the significant decrease in
immunostaining obtained when the antiserum was immunoab-
sorbed with (200 nglml) of purified hIGF-I (R&D Systems,
Minneapolis, MN, USA) prior to staining (Fig. 1 C and D).
Quantification of IGF-I mRNA abundance
To compare the relative abundance of IGF-I mRNA in the
chondrocytes of the different regions of the growth plate from the
different groups of animals, tissue sections from the three groups
of animals (sham control, uremic, and uremic treated with GH)
were mounted onto the same slides and the in situ hybridization
performed under identical conditions. Autoradiographic grains
over each respective chondrocyte cell type were counted by a
blinded observer using the method previously described [241.
Grain counts were performed on 500 to 600 randomly selected
cliondrocytes from the proliferative and hypertrophic zones of the
growth plate from each animal from the three different groups.
The grain counts over the matrix of similar surface area adjacent
to the respective zones were used as the background and they
were subtracted from the grain counts over the cells. The results
expressed as grains/cell (mean SEM) are shown in Table 5.
Statistical analysis
Anthropomorphic measurements, serum biochemical data, and
food intake/efficiency were compared using the one way analysis
Table 2. Biochemical data in the different groups at 70 days after
completion of treatment
Data S Nx Nx+GH
Serum biochemical data
SUN mg/dl
Creatinine mg/dl
Serum IGF
IGF-I ng/ml
13 2
0.4 0
171 82
63 8"1 o"
194 56
61 17"
1 0h
218±48
Data are mean so. SUN is serum urea nitrogen.
"P < 0.05 Nx vs. S
bp <0.05 Nx + GH vs. S
of variance and the post-hoc Tukey's procedure with an alpha
level set at <0.05 for significance.
Total plate width, respective zone measurements, and the ratio
of the respective zones to total plate width were compared using
the Nested analysis of variance with the post-hoc Tukey's multiple
comparison procedure. Confidence intervals were set at the 95th
percentile, and statistical significance was considered present at a
P value of <0.05.
IGF-I mRNA counts were compared using the one way analysis
of variance with significance set at a P value of <0.05.
Results
Anthropomorphic data
All the rats were of similar weights and lengths in the beginning
of the experiment, but following a two stage nephrectomy and the
development of uremia, the Nx rats were significantly lower in
weight (P < 0.05) but not in length compared to S animals (Table
1). Treatment with rhGH significantly increased the weight of the
Nx rats (P < 0.05). At the end of the treatment period, the lengths
of the Nx + GH rats, were similar to those of the S animals. The
lengths of the Nx rats were significantly less (P < 0.05) than the S
animals.
Biochemical data
Table 2 represents the biochemical data at the end of the
treatment period. The serum urea nitrogen and creatinine levels
in the Nx and Nx + GH treated rats were significantly higher (P <
0.05) than in the S animals. Serum IGF-I levels were not different
between the Nx and S animals. Treatment with rhGH in the Nx
animals increased serum IGF-I levels slightly, but this did not
achieve statistical significance.
Food intake/efficiency
Food intake (Fl) of the Nx and Nx + GH treated animals were
not different. Fl of the Nx and Nx + GH rats were significantly
lower than that of the S animals (Table 3). However, food
efficiency (FE, grams weight gained/grams food consumed) during
the treatment period was significantly enhanced in the Nx + GH
treated animals compared to the Nx and S animals (P < 0.05).
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Table 3. Food intake and food efficiency
Data S Nx Nx + GH
Food intake
Total g 939 127 637 66' 741 91"
With Rgm 481 85 325 42' 384 36"
Food efficiency
Total 0.29 0.02 0.3 0.02 0.3 0.03
With R
______
0.17 0.02 0.20 0.04 0.36 0.15"
Data are mean SD. Food efficiency was g calculated as weight gain/g
food consumed. R is treatment with rhGH or saline. Food intake and
food efficiency of different groups of rats showing total food intake/food
efficiency (from 30 to 70 days of age) and food intake/food efficiency with
treatment (from 56 to 70 days of age).
P < 0.05 Nx vs. S
"P <0.05 Nxvs. Nx + GH
"P < 0.05 Nx + GH vs. S
Growth plate morphometrics
Total plate widths of the tibia! epiphyseal growth plates from
the Nx animals were slightly lower compared to S animals, but not
significant statistically (Table 4). Treatment with rhGH signifi-
cantly increased the total plate widths of the tibial epiphyseal
growth plates from the Nx animals (P < 0.05). A more detailed
analysis of the zones comprising the growth plate revealed that in
the Nx animals rhGH increased the width of the hypertrophic
zone significantly (P < 0.05). The proliferative zone width also
appeared to be increased, but this did not achieve statistical
significance. The hypertrophic zone appeared to occupy a greater
proportion and the proliferative zone a lesser proportion of the
total plate width in the Nx + GH animals compared to the Nx
animals, hut these values did not achieve statistical significance.
The proliferative zone in the Nx + GH rats, however, comprised
significantly less of the total plate width than in the growth plates
of the S rats (P < 0.05). An additional gross morphometric
observation was that treatment with rhGH resulted in more
organized columns of chondrocytes in the Nx + GH compared to
those of the Nx rats (Fig. 2 D and F). This effect was most notable
within the chondrocytes of the proliferative layer.
IGF-I in situ hybridization and immunohistochemistiy
In situ hybridization demonstrated the expression of IGF-I
mRNA in chondrocytes of both the proliferative and hypertrophic
zones in all three groups of rats (Table 5, Figs. I and 2). The
relative IGF-l mRNA abundance expressed as autoradiographic
grains/cell in the chondrocytes of both the proliferative and
hypcrtrophic zones of the Nx rats were less than those in S rats
(Table 5, Fig. 2 A and C; P < 0.05). The increase in the relative
IGF-I mRNA abundance was not due to an increase in cell size in
either zone. This was shown by measurement of the cell surface
area of 300 randomly selected cells from zones of growth plates
from all three groups using an image analysis system (Bioquant
Meg IV system, R & M Biometrics Inc.). An increase in IGF-l
mRNA abundance was observed with GH treatment in chondro-
cytes of both the proliferative and hypertrophic zones. This
increase was significant in the chondrocytes of the proliferative
zone of the Nx + GH versus Nx rats (P < 0.05). Despite the
enhancement of TGF-l mRNA abundance in the chondrocytes of
Nx + GH rats, they were still below those of the S rats.
IGF-I immunoreactivity was detected in the chondrocytes of
both the proliferative and hypertrophic zones within the tibial
Table 4. Growth plate morphometrics
Total plate width Hypertrophic zone Proliferative zone
Group pm
S
Nx
Nx + GH
Group
367 22
341 20"
417 17
165
153
212
17
15"
13
112 9.0
84 8.0
91 7.0
Hypertrophic
zone/TPW
Proliferative
zone/TPW
S
Nx
Nx + GH
—
45 2.0%
45 2.0%
50 1.0%
30 2.0%
24 2.0%
22 2.0%"
Data are mean so.TPW is total plate width. Tibial epiphyseal growth
plate morphometrics of different groups of rats showing total plate width,
hypertrophic zone width and proliferative zone width, and the proportions
of hypertrophic zone width or proliferative zone width to the total
epiphyseal growth plate width.
ap <0.05 Nxvs. Nx + GH
"P < 0.05 Nx + GH vs. S
epiphyseal growth plates of all animals. In the growth plates of Nx
and S rats the majority of IGF-I immunoreactivity was observed in
the chondrocytes of the hypertrophic zone. Chondrocytes of the
proliferative zone showed variable immunoreactivity with a more
consistent immunostaining observed in those near the hypertro-
phic zone (Fig. 2 B and D). In the rhGH treated Nx rats IGF-I
immunoreactivity was present in chondrocytes of both zones, but
compared to the untreated animals (Fig. 2D), immunoreactivity
was observed in greater numbers of chondrocytes within the
proliferative zone (Fig. 2F).
Discussion
This study confirms previous reports which have shown that
supplemental treatment with GH improves the linear growth of
uremic animals [3 1—341 and children with chronic renal failure
[14—171. However, the results of this study differ from those of
previous reports in that GH treatment had a statistically signifi-
cant effect on the weight gain and on the growth plate morpho-
metrics in long bone, but not on the nose-tail length of Nx
animals. The variable response of uremic animals to GH treat-
ment is in keeping with previous reports which have shown
increases either in both weight and length [32, 34J, or length only
[331 or neither [181. These results could be attributable to
differences in the age of the animals, severity of uremia, and mode
and dose of GH treatment. As reported in previous studies [31,
321, we also demonstrated that the increase in weight of Nx + GH
animals was attributable to a significant improvement in food
efficiency, even though the food intake was not significantly
different from the untreated uremic counterparts. A similar effect
on food efficiency was noted between the Nx + GH and S rats,
despite greater intake and weight gain in the latter. Since serum
IGF-I concentrations were not significantly different between the
three groups of rats, the improved food efficiency could not be due
to the endocrine effects of IGF-I resulting from GH treatment.
GH has been shown to exert direct effects on chondrocytes in vitro
in which the action of GH was shown to potentiate the effects of
IGF-I [35, 361. It is possible that GH may have a direct effect on
the peripheral tissues by either increasing the synthesis of IGF-I
locally which will then act in autocrine/paracrine manner on tissue
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Fig. 2. Dark field (A, C and E) and bright field (B, D and F) photomicrographs of tibial epiphyseal growth plates from S (A and B), Nx (C and D) and Nx
+ GH (E and F) rats, hybridized in Situ with 35S-radiolabeled rat IGF-1 antisense RNA probe (A, C and E), and immunostained with a specific antiserum
against IGF-i (B, D and F). Scale bar = 100 sm. P proliferative zone, H = hypertrophic zone.
growth [371, or by increasing tissue responsiveness to IGF-I by
affecting tissue IGF-I receptors [38, 39} or IGFBPs [40].
Even though the nose-tail length was not statistically increased
in Nx + GH animals in contrast to a previously reported study
we have shown a significant increase in the total plate widths
of the tibial epiphyseal growth plates in these animals. The
increase in width was observed in both the proliferative and
hypertrophic zones, but a statistically significant change was noted
only in the hypertrophic zone. In a similar study, Mehls et a! [32]
reported that a statistically significant increase in total plate width
yAI— —iZ frra._S L Sej.ç' _________________
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Table 5. Relative abundance of IGF-I mRNA (mean SEM)
Group
Hypertrophic_zone Proliferative zone
grains/cell
S 20±1.6 9±0.7
Nx 12 0.8" 4 0.8"
Nx + OH 16 12b 7 0.5"
"P <0.05 Nxvs. S
bP < 0.05 Nx + GH vs. S
"P < 0.05 Nx + GH vs. Nx
resulted from an increase in the width of the hypertrophic zone
from persistence of cartilage cells within the growth plates of
uremic OH treated rats compared to nephrectomized counter-
parts. In our study, whether the increase was due to an increase in
the number or size of chondrocytes occupying the hypertrophic
zone is not known, since a detailed morphometric analysis of each
cell type was not performed. Hypophysectomized animals treated
with GH respond with a significant increase in total plate width
similar to Nx animals [5, 7, 8].
It is of interest to note that both the IGF-I mRNA and IGF-I
peptide were detectable in chondrocytes of both the proliferative
and hypertrophic zones of the tibial epiphyseal growth plates in
the sham operated rats. Although chondrocytes of both zones
expressed IGF-I mRNA, IGF-I immunoreactivity was detected
more consistently in those of the hypertrophic zone. This is similar
to our previois report in older rats of 18 weeks which demon-
strated IGF-l mRNA and peptide in both zones of the growth
plate with more prominent immunoreactivity in the hypertrophic
zone [24]. The presence of IGF-I immunoreactivity suggests the
cells to be either sites of synthesis or action, or both. The
differential immunoreactivity observed among the chondrocytes
of the proliferative zone and between the cells of the hypertrophic
and proliferative zones, both of which contain IGF-I mRNA,
indicates that mechanisms other than synthesis may be responsi-
ble for the positive IGF-I immunoreactivity. IOF immunoreactiv-
ity has been shown to be co-localized with that of IGFBPs [411 and
it is therefore possible that the differential immunoreactivity
observed is due to the differential localization of IGFBPs. The
IGF-I immunoreactivity in S animals, however, differed slightly
from the previous report which showed a greater intensity of
immunostaining in the proliferative zone chondrocytes [71, a
pattern similar to that observed in our Nx + GH animals. It is
possible that the difference in the ages of the rats used in the two
studies (70 days in this study vs. 33 days in the previous study), as
well as the model used (hypophysectomized rat vs. uremic rat)
could be the reason for this difference in IGF-I immunoreactivity.
At 70 days of age, the rats are more mature and are at the end of
their active phase of linear growth. Similarly, our in situ hybrid-
ization for IGF-I mRNA differed from those of Shinar et al [42]
who found no IGF-I mRNA within the growth plate of three- to
five-week-old rats. In contrast, we have demonstrated the expres-
sion of IGF-I mRNA in chondrocytes of both the proliferative and
hypertrophic zones of adult rats, indicating that these chondro-
cytes have the capacity to synthesize IGF-I [24]. These differences
maybe explained by the age of the animals, and the methodologic
differences in the procedure (tissue fixation, exposure time,
sensitivity of detection of probe). The present study gives further
support to the concept that local synthesis of IGF-I occurs within
the growth plate.
In nephrectomized animals the IGF-I mRNA abundance ap-
peared to be lower in both the proliferative zone and hypertrophic
zone chondrocytes with no apparent change in IGF-I immunore-
activity in both zones compared to the S animals. Morphometric
studies, however, showed that there was no difference in the total
plate widths between the Nx animals and S animals. These
findings indicate that uremia causes a decrease in the local
expression of IGF-I mRNA in the growth plate chondrocytes with
a potential to alter growth of these cells. Since plasma IGF-I
concentrations were not changed, it is possible that growth plate
chondrocytes utilize the circulating IGF-I to maintain normal
growth, as evident by the similar IGF-I immunoreactivity of
growth plate chondrocytes between S and Nx animals. Such a
differential response of tissues to systemic pathology was observed
in fetuses subjected to hypoxia [43].
Our finding demonstrating an increase in IGF-I gene expres-
sion in the proliferative zone of the tibial epiphyseal growth plate
in Nx rats treated with rhGH suggests that OH stimulates the
presence of IGF-I in these cells, either by increasing GH receptor
binding sites, and/or IGF-I synthesis or binding in an autocrine
manner. This finding is similar to the previous report by Nilsson et
al [6, 71, who demonstrated that widening of the epiphyseal
growth plate in hypophysectomized rats treated with rhGH is
accompanied by an enhancement of IGF-I mRNA and immuno-
reactivity in the proliferative zone chondrocytes. Whether the GH
mediated enhancement of IGF-I gene expression observed in the
uremic rats as well as hypophysectomized animals is due to an
increase in GH binding, an increase in IGF-I synthesis by growth
plate chondrocytes, or an increase in binding of IGF-I to its
receptors or binding proteins [12, 38—40] remains to be resolved.
No studies have been done to date to evaluate differential
regulation of IGF-I receptor from IGF-I protein in uremia. A
previous study has shown the number of OH binding sites in liver
membranes are decreased in uremia No treatment with GH
to evaluate its effect on binding or altering the number of binding
sites was attempted in the study. GH receptor mRNA in the liver
of uremic rats has been shown to be significantly depressed in
uremia and not to be induced by GH treatment, suggesting that
differential regulation of GH from its receptor mRNA is present
in uremia [45]. Growth hormone has been shown to increase
IGF-I receptors in various cell types, and it is possible that a
similar effect is present in the chondrocytes of the proliferative
zone [38, 39]. The effects of GH on enhancing IGF-I mRNA and
immunoreactivity in the proliferative chondrocytes, increasing
IGF-I mRNA abundance in the hypertrophic zone chondrocytes,
and increasing the width of the hypertrophic zone in the tibial
epiphyseal growth plates of Nx animals suggest that OH may have
a dual role in promoting linear growth in these animals: in the
chondrocytes of the proliferative zone, its actions may be medi-
ated by increasing local IGF-I, and in those of the hypertrophic
zone it increases the IGF-I responsiveness by influencing IGF-I
receptors or IGFBPs [461 or shifting the biological function of
IGF-I to that of inducing differentiation or potentiating matura-
tion. The possibility of GH having a direct action on the these cells
[3, 41 or indirectly via other growth factors [47—49] cannot be
excluded also.
The finding that the width of the proliferative zone was
unchanged despite the enhanced IGF-I mRNA expression and
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protein staining in this zone suggests either an inability of these
cells to respond to the growth promoting actions of IGF-I as has
described recently in liver from uremic GH treated rats [45], or
that IGF-I enhances differentiation of the proliferative zone
chondrocytes, and therefore the proliferative zone width re-
mained unchanged whereas the hypertrophic zone width in-
creased. In the tibial epiphyseal growth plates of the older
animals, IGF-I could either directly exert itself, or through a GH
induced potentiation of IGF-I's effects [35, 36] exert a more
pronounced influence on the differentiation of the mature chon-
drocytes, resulting in enhancement of the components represent-
ing IGF-I immunoreactivity in these cells [50—52]. A similar role
for IGF-I in osteoblast differentiation has been suggested [24,42],
and a shift in IGF-I action from promoting cell division to
potentiating maturation has been shown in other cell types [53].
In summary, we have demonstrated that rhGH supplementa-
tion of uremic animals improves weight gain by increasing the
food efficiency, and longitudinal growth by directly acting on the
growth plates of long bones. Growth hormone appears to act on
the uremic tibia! epiphyseal growth plate by increasing IGF-I gene
expression in the proliferative zone chondrocytes, and by expand-
ing the height of the hypertrophic zone chondrocytes. This
increase in IGF-I gene expression was not accompanied by an
increase in proliferative zone width, which may be due to target
tissue resistance to the actions of IGF-I peptide or to the
enhancement of differentiation of these chondrocytes resulting in
an increase in the width of the hypertrophic zone. The latter may
also be due to either a direct action of GH on these chondrocytes
or indirectly via increasing responsiveness of these cells to locally
produced IGF-I,
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